Distinction of ALK fusion gene‐ and EGFR mutation‐positive lung cancer with tumor markers
Thoracic Cancer · 2024
DOI: 10.1111/1759-7714.15268 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2024. Verfasst von Takahiro Akita und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Carcinoma, Non-Small-Cell Lung, Keratin-19, Lung Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
It is difficult to predict gene mutations individually based on clinical background alone. Tumor markers may help to predict each gene mutation. Identifying tumor markers that can predict gene mutation will facilitate timely genetic testing and intervention.
Methods
We selected 134 cases of advanced or recurrent ALK‐positive and 172 cases of advanced or recurrent EGFR‐positive lung cancer from our clinical database. The cutoff values for the tumor markers were defined as 5.0 ng/mL or higher for carcinoembryonic antigen (CEA) and 3.5 ng/mL or higher for soluble fragment of cytokeratin 19 (CYFRA21‐1) in accordance with the institutional standards. A positive CYFRA21‐1:CEA ratio was defined as 0.7 or higher.
Results
The CEA‐positivity rate was 49% for ALK‐positive lung cancers and 73% for EGFR‐positive lung cancers, which was significantly different ( p < 0.001). The CYFRA21‐1 positivity rate was significantly higher in ALK‐positive lung cancer (36%) compared with EGFR‐positive lung cancer (23%) ( p = 0.034). The median CYFRA21‐1:CEA ratio was 0.395 for the ALK group, which was significantly higher compared with 0.098 for the EGFR group ( p < 0.001). These trends were similar when excluding histology other than adenocarcinoma. The median time‐to‐treatment failure (TTF) for initial tyrosine kinase inhibitor (TKI) therapy was 308 days for the high CYFRA21‐1:CEA ratio group and 617 days for the low CYFRA21‐1:CEA ratio group for ALK‐positive lung cancer ( p = 0.100).
Conclusions
A higher proportion of patients with ALK‐positive lung cancer were CYFRA21‐1 positive and had higher CYFRA21‐1:CEA ratios compared with EGFR‐positive lung cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
- Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
ORCID-Profile: Ryo Ariyasu, Yoshiaki Amino, Ken Uchibori, Makoto Nishio
Zitieren
APA
Akita, T., Ariyasu, R., Kakuto, S., Miyadera, K., Kiritani, A., Tsugitomi, R., Amino, Y., Uchibori, K., Kitazono, S., Yanagitani, N., Tasaka, S., & Nishio, M. (2024). Distinction of ALK fusion gene‐ and EGFR mutation‐positive lung cancer with tumor markers. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15268
Vancouver
Akita T, Ariyasu R, Kakuto S, Miyadera K, Kiritani A, Tsugitomi R, et al. Distinction of ALK fusion gene‐ and EGFR mutation‐positive lung cancer with tumor markers. Thoracic Cancer. 2024. doi:10.1111/1759-7714.15268
BibTeX
@article{Akita2024,
author = {Akita, Takahiro and Ariyasu, Ryo and Kakuto, Sho and Miyadera, Keiki and Kiritani, Ayu and Tsugitomi, Ryosuke and Amino, Yoshiaki and Uchibori, Ken and Kitazono, Satoru and Yanagitani, Noriko and Tasaka, Sadatomo and Nishio, Makoto},
title = {Distinction of ALK fusion gene‐ and EGFR mutation‐positive lung cancer with tumor markers},
journal = {Thoracic Cancer},
year = {2024},
doi = {10.1111/1759-7714.15268}
}
EUVIMED